石酸可通过抑制囊生物合成来抑制肺炎链球菌感染
Sanwei Gu1,2, Jian Zhang2, Xiaoye Fan1
1Department of Respiratory Medicine, Center for Pathogen Biology and Infectious Diseases, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, State Key Laboratory for Zoonotic Diseases, The First Hospital of Jilin University, Changchun, China.
Communications biology
|January 9, 2026
概括
史蒂维oside 通过破坏 pyruvate 代谢来抑制 Streptococcus pneumoniae 囊的形成. 这种天然化合物提供了针对抗生素耐药性和非疫苗血清型感染的新策略.
科学领域:
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
- 生物化学 生物化学
背景情况:
- 尽管有疫苗,但Streptococcus pneumoniae会导致儿童和老年人死亡率显著.
- 细菌囊对于S. pneumoniae的致病性至关重要,使其成为一种关键的药物标.
- 需要采取替代策略来对抗抗生素耐药性和非疫苗血清型S. pneumoniae感染.
研究的目的:
- 为了确定抑制S. pneumoniae囊生物合成的天然化合物.
- 研究已识别的抑制剂的作用机制.
- 评估这些化合物对S. pneumoniae感染的治疗潜力.
主要方法:
- 确定了化作为一个囊生物合成抑制剂.
- 研究了石酸对酸盐代谢和NAD+/NADH平衡的影响.
- 在实验室中评估了石化对细菌抗压力,补充抗性,粘附性和细胞的影响.
- 在S. pneumoniae感染的小鼠模型中评估了stevioside的疗效.
主要成果:
- 史蒂维oside 通过干扰 pyruvate 的新陈代谢,减少了囊中的多糖生物合成.
- 该化合物破坏了细菌的氧化还原平衡和能量生成.
- 石化使S. pneumoniae对抗菌和压力敏感,并减弱了囊介导的抵抗机制.
- 在体内,石酸治疗改善了感染小鼠的生存率和减少了病理学.
结论:
- 石化是一种有前途的化合物,用于开发针对S. pneumoniae的新型化学囊抑制剂.
- 准pyruvate代谢为发现S. pneumoniae囊抑制剂提供了一个新的策略.
- 石酸在对抗S. pneumoniae感染,包括耐药菌株方面显示出治疗潜力.
相关概念视频
01:31Defense Against Bacterial Pathogens
2.6K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
2.6K
01:28Peptidoglycan Synthesis
2.0K
Structure of PeptidoglycanPeptidoglycan is a vital structural component of the bacterial cell wall, providing mechanical strength and shape to the cell. It consists of repeating units of two sugars—N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM)—linked by β-1,4 glycosidic bonds. These sugar chains are cross-linked by short peptide chains, forming a mesh-like polymer that surrounds the bacterial plasma membrane.Cytoplasmic Phase – Precursor SynthesisPeptidoglycan...
2.0K
01:28Antimicrobial Effectiveness
897
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
897
01:27Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
01:17Gram-negative Bacterial Protein Secretion Systems
753
Gram-negative bacteria utilize sophisticated protein secretion systems to transport proteins across their double-membrane envelope into the extracellular environment or host cells. Based on their mechanism of action, these systems are classified into one-step and two-step pathways.One-Step Secretion Systems (Types I, III, IV, and VI)One-step secretion systems bypass the periplasm entirely, forming a continuous channel that spans both the inner and outer membranes:Type I Secretion System (T1SS):...
753
01:28Pneumonia IV: Management
749
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
749